Senseonics Holdings, Inc.

As of August 10, 2023, Senseonics Holdings, Inc. is considered overvalued with a risky outlook due to poor financial metrics, including a Price to Book Value of 11.29 and negative EV to EBIT and EV to EBITDA ratios, while its 11.02% return over the past year lags behind the S&P 500's 17.14%.

As of August 10, 2023, Senseonics Holdings, Inc. is considered overvalued and risky due to poor financial ratios, including a Price to Book Value of 11.29 and a ROCE of -1158.47%, and it has underperformed compared to its peers and the S&P 500.

As of June 18, 2025, the technical trend is mildly bearish, indicated by bearish weekly MACD and Bollinger Bands, a bearish monthly RSI, and a mildly bearish OBV, despite some mixed signals from moving averages and KST.

As of March 2022, the management team of Senseonics Holdings, Inc. includes Mr. Stephen DeFalco (Independent Chairman), Dr. Timothy Goodnow (CEO), Dr. Francine Kaufman (CMO), and several directors, including Mr. Anthony Raab, Mr. Robert Schumm, Dr. Steven Edelman, Mr. Edward Fiorentino, and Dr. Peter Klein. This team combines executive leadership with independent oversight to guide the company's strategy.

Senseonics Holdings, Inc. is a medical technology company specializing in glucose monitoring systems. As of March 2025, it reported net sales of $6 million and a net loss of $14 million, with a market cap of $376.84 million.

As of Jun 18, Senseonics Holdings, Inc. has a market capitalization of 376.84 million, with net sales of 23.69 million and a net profit of -74.01 million over the last four quarters. Shareholder's funds are 21.10 million, and total assets are 100.44 million.